

Media contact: Reese A. Nank, APR • 410-218-9121 • reputationspr@cox.net  
Company contact: Mark Keck, Vice President, Marketing • T: 216-332-1665 x106 • mkeck@chantest.com

## FOR IMMEDIATE RELEASE

### ChanTest CEO to Speak on New Pre-Clinical Assays for Predicting Cardiotoxicity at Society of Toxicology Annual Meeting

#### ChanTest to Host Webinar March 23

**March 4, 2010, CLEVELAND** – Arthur “Buzz” Brown, founder, president and CEO of ChanTest and renowned authority on cardiotoxicity in drug development, will speak on the subject at the annual meeting of the Society of Toxicology in Salt Lake City, Utah on March 8. Dr. Brown’s session, which addresses the problem of sudden cardiac death due to non-cardiac drugs (a major safety issue for the pharmaceutical industry and U. S. regulatory bodies), will be held in Room 155 C from 3:30 p.m. – 4:30 p.m. MST in the Salt Palace Convention Center.

Dr. Brown will present the newest pre-clinical assays for cardiotoxicity assessment and the application/interpretation of pharmacologically relevant data sets. Particular attention will be given to enhancing predictivity and avoiding current discordances between S7B-recommended assays (hERG, *in vivo* QT) and Phase I observations.

Dr. Brown is a recognized expert in the field of molecular physiology and pharmacology of ion channels and their clinical relevance for cardiac drug safety. His lab was the first to identify the hERG potassium channel as the unintended target for the cardiotoxic effects of Seldane and Propulsid, both of which were subsequently withdrawn from the market. Subsequent work in his laboratory led to the discovery of hERG trafficking inhibition by drugs that may cause sudden cardiac death.

For those interested in new assays to improve cardiac risk evaluation but unable to attend the toxicology conference, Dr. Brown will provide further details about the influence of other cardiac ion channels on repolarization, ion channel trafficking assays, and the adoption of more relevant *in vitro* models (SC-derived cardiomyocytes) at a free webinar.

To register for the Tuesday, March 23 webinar at 11 a.m. EDT, go to: [www.chantest.com](http://www.chantest.com).

#### **About ChanTest Corporation ([www.chantest.com](http://www.chantest.com))**

ChanTest’s mission is to serve the research, drug discovery and drug development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest’s seminal role in the pre-clinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail [info@chantest.com](mailto:info@chantest.com).

###